What is 5-Amino-1MQ, and why is a non-peptide in a peptide catalogue?
5-Amino-1MQ, 5-amino-1-methylquinolinium, is a small molecule, not a peptide: a quinolinium cation of formula C10H11N2+, mass 159.2, CAS 685079-15-6, supplied as a salt. It is a membrane-permeable inhibitor of nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and competes with NAD+ salvage, and it is in the catalogue because it appears in the same adipocyte and NAD+ metabolism research as the peptides around it. The material is for in-vitro research only.
What is the structure of 5-Amino-1MQ?
A methylated quinoline ring bearing an amino group at position 5, carrying a permanent positive charge on the ring nitrogen. The certificate reports it as an orange lyophilized powder, the one coloured non-copper lot in the library, and confirms the cation mass of 159.2 by LC-MS/MS. The counter-ion contributes to the vial's mass but not to the identity line.
| Identifier | Value |
|---|---|
| Molecular formula | C10H11N2+ (cation) |
| Molecular weight | 159.21 g/mol |
| Residues | not recorded |
| CAS number | 685079-15-6 |
| PubChem CID | 950107 |
| Current lot | 5AM1MQ50-0803 |
How is 5-Amino-1MQ thought to work?
Competitive inhibitor of nicotinamide N-methyltransferase, reported by Neelakantan and colleagues in 2017 with cellular activity in adipocytes; inhibiting the enzyme spares nicotinamide for NAD+ synthesis and lowers 1-methylnicotinamide. The enzyme target is defined and the compound is used as a tool for it.
Which research areas use 5-Amino-1MQ?
| Area | Typical models and endpoints |
|---|---|
| NNMT enzymology | Inhibition assays with recombinant enzyme. |
| NAD+ metabolism | Nicotinamide and NAD+ measurements in cultured adipocytes and muscle cells. |
| Adipocyte models | Differentiation and lipid-accumulation readouts in 3T3-L1 cells. |
| Small-molecule versus peptide handling | A case study in solubility and stability differences from the rest of the catalogue. |
What does the published literature show?
Neelakantan et al. (Journal of Medicinal Chemistry, 2017) described the inhibitor series and effects in mice; a 2018 Biochemical Pharmacology report from the same group examined muscle stem cells. There is no clinical programme; research use is in-vitro and preclinical.
How is 5-Amino-1MQ handled in the laboratory?
Water-soluble as the salt; stable in solution for far longer than a peptide, with no residues to oxidise or hydrolyse. Light-protect as a precaution for a conjugated aromatic. Store lyophilized at room temperature or refrigerated per the certificate; freezing is unnecessary. The concentration table covers volumes and syringe units; the storage guide covers stability by compound class.
What does the current certificate show?
Lot 5AM1MQ50-0803 tested at 99.87% purity by RP-HPLC (214 nm), identity confirmed by LC-MS/MS, endotoxin <0.05 EU/mL. The certificate is in the COA library and the lot number on the vial matches it. Sold as 50 mg per vial at $80, for laboratory research only.
Certificate history for 5-Amino-1MQ
Every certificate the library holds for this compound, newest first. A replaced lot stays listed so the history can be read; the certificate dataset reads all 114 together.
| Lot | Issued | Size | Identity | Purity | Content | Status |
|---|---|---|---|---|---|---|
| 5AM1MQ50-0803 | Aug 17, 2026 | 50 mg | LC-MS/MS | 99.87% | 50.98 mg | Current |
Frequently asked questions
Is it really not a peptide?
Correct. It is a quinolinium small molecule with no amino acids. It is listed because its research context overlaps with the NAD+ and metabolic peptides, and the catalogue says so.
What does the current certificate show?
Lot 5AM1MQ50-0803: identity by LC-MS/MS at 159.2, purity 99.87% by RP-HPLC at 214 nm, content 50.98 mg, endotoxin below 0.05 EU/mL, heavy metals below 0.01 ppm. Issued 17 August 2026.
Why is the mass given for a cation?
Because the active species is the positively charged quinolinium ring; the counter-ion in the salt is separate and the certificate identifies the cation.
References
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152.
- Neelakantan H, Wang HY, Vance V, Hommel JD, McHardy SF, Watowich SJ. Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. J Med Chem. 2017;60(12):5015-5028.
- PubChem CID 950107, 5-Amino-1-methylquinolinium. National Library of Medicine. Read 2 October 2026.
Clinical results cited above describe regulated trials of pharmaceutical products and are given as context for research interest only. Nothing on this page describes or recommends use of the material sold here in humans or animals.
5-Amino-1MQ 50 mg
$80 per vial
Lot 5AM1MQ50-0803 · 99.87% RP-HPLC (214 nm) · certificate published
View productRelated
- NAD+ research guide · NAD+ 500 mg
- MOTS-c research guide · MOTS-c 10 mg
- 5-Amino-1MQ is not a peptide: what it is, what NNMT does, and how to read its certificate
- AOD-9604: the growth hormone fragment 176-191, its disulfide loop, what the rodent studies measured, and what a 5 mg certificate shows
- Thymalin vs thymulin: two names, two different things, and what the catalogue certificate's mass of 858.8 actually matches
- Thymosin alpha-1: the 28-residue sequence, the certificate for lot TA110-0803 line by line, and its regulatory status
- Glossary of certificate terms
